Latest From Genmab AS
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Join the London-based Eleanor Malone, Andrew McConaghie and Kevin Grogan as they review some of the most eyecatching stories in pharma and healthcare.
The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Genmab AS
- Senior Management
Jan van de Winkel, PhD, Pres. & CEO
David A Eatwell, EVP, CFO
Judith Klimovsky, MD, EVP, Chief Dev. Officer
- Contact Info
Phone: (45) 7020 2728
Kalvebod Brygge 43
Copenhagen, 1560 V
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.